Currently out of the existing stock ratings of Jason Kolbert, 319 are a BUY (94.66%), 3 are a SELL (0.89%), 15 are a HOLD (4.45%).

Jason Kolbert

Work Performance Price Targets & Ratings Chart

Analyst Jason Kolbert, carries an average stock price target met ratio of 33.96% that have a potential upside of 30.46% achieved within 403 days. Previously, Jason Kolbert worked at DAWSON JAMES.

Jason Kolbert’s has documented 581 price targets and ratings displayed on 61 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ARTL, Artelo Biosciences at 06-Jun-2025.

Wall Street Analyst Jason Kolbert

Analyst best performing recommendations are on ABUS (ARBUTUS BIOPHARMA CORP).
The best stock recommendation documented was for ABUS (ARBUTUS BIOPHARMA CORP) at 12/22/2014. The price target of $21 was fulfilled within 21 days with a profit of $7.81 (59.21%) receiving and performance score of 28.2.

Average potential price target upside

of $1033.2 (99.96%) on GLMD (GALMED PHARMACEUTICALS LTD).
of $101 (39.08%) on AEZS (AETERNA ZENTARIS).
of $92.57 (102.19%) on INO (INOVIO PHARMACEUTICALS).

ADMP Adamis Pharma AEZS Aeterna Zentaris ATHX Athersys BCLI Brainstorm Cell Therapeutics BLRX BioLineRx Ltd CTXR Citius Pharmaceuticals FBIO Fortress Biotech GILD Gilead Sciences GLMD Galmed Pharmaceuticals Ltd INO Inovio Pharmaceuticals ISR IsoRay MESO Mesoblast Ltd MNKD MannKind Corp NTEC Intec Pharma Ltd OMER Omeros PSTI Pluristem SRNE Sorrento Therape ACHN Achillion Pharmaceuticals CLBS Caladrius Biosciences TEVA Teva Pharma Industries Ltd ADR VRTX Vertex Pharmaceuticals AVXL Anavex Life Sciences Corp PSTV Plus Therapeutics PRPH ProPhase Labs BCDA Biocardia ADMA ADMA Biologics BGNE BeiGene Ltd CFRX ContraFect Corp CHEK Check Cap Ltd SNGX Soligenix CANF Can Fite Biopharma Ltd ADR ONCS OncoSec Medical DYAI Dyadic International ABUS Arbutus Biopharma Corp CHRS Coherus BioSciences CTSO Cytosorbents Crp DARE Dare Bioscience ANVS Annovis Bio ARTL Artelo Biosciences BMEA Biomea Fusion IBRX Immunitybio CLNN Clene CMPX Compass Therapeutics CRMD CorMedix ENLV Enlivex Therapeutics Ltd GOVX GeoVax Labs HOTH Hoth Therapeutics HUMA Humacyte IMUX Immunic IVVD Invivyd NRXP NRX Pharmaceuticals RCEL Avita Medical Ltd RVPH Reviva Pharmaceuticals Holdings TRVI Trevi Therapeutics URGN UroGen Pharma Ltd BJDX Bluejay Diagnostics CLGN Collplant Biotechnologies Ltd COYA Coya Therapeutics, Common Stock CRVO CervoMed MNOV MediciNova SNOA Sonoma Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Jason Mccarthy (MAXIM GROUP)